Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy
J. Natl. Cancer Inst. Veronesi et al.
99: 727
Supplementary Data
Files in this Data Supplement:
- Supplementary Table 1 -
Numbers and rates of breast cancer in the placebo and tamoxifen groups by selected tumor characteristics
- Supplementary Table 2 -
Numbers and incidence rates of minor adverse events in the placebo and tamoxifen groups during treatment
- Supplementary Table 3 -
Numbers and incidence rates of cardio- and cerebrovascular adverse events in the placebo and tamoxifen groups during treatment
- Supplementary Table 4 -
Numbers and incidence rates of invasive cancers other than breast in the placebo and tamoxifen groups
- Supplementary Fig. 1 -
Cumulative incidence of selected adverse events during treatment.
The number of women on treatment in the tamoxifen and in the placebo group were 2700 and 2708 at baseline, 2222 and 2317 after 1 year, 2031 and 2150 after 2 years, 1879 and 1940 after 3 years, 1730 and 1797 after 4 years, 1263 and 1352 after 5 years, respectively. Hazard ratios (HRs) and 95% confidence intervals) were calculated from a Cox regression model adjusted for age and center. †, among women free of symptoms at baseline.
- Supplementary Fig. 2 -
Cumulative incidence of hypertriglyceridemia. The number of women on treatment in the tamoxifen and in the placebo group were 2700 and 2708 at baseline, 2222 and 2317 after 1 year, 2031 and 2150 after 2 years, 1879 and 1940 after 3 years, 1730 and 1797 after 4 years, 1263 and 1352 after 5 years, respectively. Hazard ratio (HR) (and 95% confidence intervals) were calculated from a Cox regression model adjusted for age and center.
- Supplementary Fig. 3 -
Cumulative incidence of cardiac, pulmonary, and cerebrovascular events during treatment. The number of women on treatment in the tamoxifen and in the placebo group were 2700 and 2708 at baseline, 2222 and 2317 after 1 year, 2031 and 2150 after 2 years, 1879 and 1940 after 3 years, 1730 and 1797 after 4 years, 1263 and 1352 after 5 years, respectively. Hazard ratios (HRs) (and 95% confidence intervals) were calculated from a Cox regression model adjusted for age and center.
- Supplementary Fig. 4 -
Cumulative incidence of non-breast cancers and deaths. Hazard ratios (HRs) (and 95% confidence intervals) were calculated from a Cox regression model adjusted for age and center.
